KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBT Margin (2016 - 2025)

Rigel Pharmaceuticals has reported EBT Margin over the past 15 years, most recently at 32.54% for Q4 2025.

  • Quarterly results put EBT Margin at 32.54% for Q4 2025, up 611.0% from a year ago — trailing twelve months through Dec 2025 was 41.4% (up 3115.0% YoY), and the annual figure for FY2025 was 41.4%, up 3115.0%.
  • EBT Margin for Q4 2025 was 32.54% at Rigel Pharmaceuticals, down from 39.76% in the prior quarter.
  • Over the last five years, EBT Margin for RIGL hit a ceiling of 58.99% in Q2 2025 and a floor of 164.0% in Q1 2022.
  • Median EBT Margin over the past 5 years was 11.51% (2023), compared with a mean of 21.48%.
  • Peak annual rise in EBT Margin hit 11396bps in 2022, while the deepest fall reached -21494bps in 2022.
  • Rigel Pharmaceuticals' EBT Margin stood at 111.23% in 2021, then skyrocketed by 102bps to 2.73% in 2022, then fell by -25bps to 2.06% in 2023, then surged by 1184bps to 26.43% in 2024, then grew by 23bps to 32.54% in 2025.
  • The last three reported values for EBT Margin were 32.54% (Q4 2025), 39.76% (Q3 2025), and 58.99% (Q2 2025) per Business Quant data.